A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting

Phase 3

Divarasib vs. SotorasibA Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor:

Hoffmann-La Roche

Code:

NCT06497556

Conditions

Non-Small Cell Lung Cancer

KRAS G12C Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Divarasib

Sotorasib

Adagrasib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-14. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2025-11-12.